Cellectar Biosciences (NASDAQ:CLRB) Stock Rating Upgraded by Brookline Capital Markets

Cellectar Biosciences (NASDAQ:CLRB) was upgraded by research analysts at Brookline Capital Markets to a “strong-buy” rating in a report issued on Sunday,Zacks.com reports. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q1 2027 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.34) EPS.

Several other research firms have also recently issued reports on CLRB. LADENBURG THALM/SH SH began coverage on shares of Cellectar Biosciences in a research note on Friday, May 15th. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Cellectar Biosciences to a “hold” rating in a research report on Saturday, June 20th. Roth Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cellectar Biosciences in a report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Cellectar Biosciences Stock Performance

Shares of CLRB stock opened at $2.63 on Friday. Cellectar Biosciences has a fifty-two week low of $2.20 and a fifty-two week high of $6.52. The firm has a market capitalization of $21.01 million, a PE ratio of -0.39 and a beta of 0.55. The stock’s 50-day simple moving average is $2.81 and its 200-day simple moving average is $2.99.

Cellectar Biosciences (NASDAQ:CLRB) last released its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping analysts’ consensus estimates of ($1.88) by $0.55. Sell-side analysts forecast that Cellectar Biosciences will post -2.34 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CLRB. XTX Topco Ltd purchased a new position in shares of Cellectar Biosciences during the 4th quarter valued at approximately $36,000. DRW Securities LLC increased its holdings in Cellectar Biosciences by 114.2% in the 4th quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 24,089 shares in the last quarter. Geode Capital Management LLC increased its holdings in Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 3,744 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in Cellectar Biosciences by 135.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 14,567 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Cellectar Biosciences during the third quarter worth $104,000. 16.41% of the stock is owned by institutional investors and hedge funds.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.